The Effect of Krill Oil Supplementation on Exercise Performance and Markers of Immune Function

Date of Acceptance: 08/09/2015 Acknowledgments We thank the technical support of the Institute of Medical Sciences Musculoskeletal Programme and the Iain Fraser Cytometry Centre.Peer reviewedPublisher PD

Discovery of an Unusually Red L-type Brown Dwarf

We report the discovery of an unusually red brown dwarf found in a search for high proper motion objects using WISE and 2MASS data. WISEP J004701.06+680352.1 is moving at 0.44$ arcsec/yr and lies relatively close to the Galactic Plane (b=5.2 degrees). Near-infrared photometry and spectroscopy reveals that this is one of the reddest (2MASS J-K_s = 2.55 +/- 0.08 mag) field L dwarfs yet detected, making this object an important member of the class of unusually red L dwarfs. We discuss evidence for thick condensate clouds and speculate on the age of the object. Although models by different research groups agree that thick clouds can explain the red spectrum, they predict dramatically different effective temperatures, ranging from 1100K to 1600K. This brown dwarf is well suited for additional studies of extremely dusty substellar atmospheres because it is relatively bright (K_s = 13.05 +/- 0.03 mag), which should also contribute to an improved understanding of young gas-giant planets and the transition between L and T brown dwarfs.Comment: Accepted to Astronomical Journal (AJ

Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices)

: In the European Union (EU) the delivery of health services is a national responsibility but there are concerted actions between member states to protect public health. Approval of pharmaceutical products is the responsibility of the European Medicines Agency, whereas authorizing the placing on the market of medical devices is decentralized to independent 'conformity assessment' organizations called notified bodies. The first legal basis for an EU system of evaluating medical devices and approving their market access was the medical device directives, from the 1990s. Uncertainties about clinical evidence requirements, among other reasons, led to the EU Medical Device Regulation (2017/745) that has applied since May 2021. It provides general principles for clinical investigations but few methodological details-which challenges responsible authorities to set appropriate balances between regulation and innovation, pre- and post-market studies, and clinical trials and real-world evidence. Scientific experts should advise on methods and standards for assessing and approving new high-risk devices, and safety, efficacy, and transparency of evidence should be paramount. The European Commission recently awarded a Horizon 2020 grant to a consortium led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, that will review methodologies of clinical investigations, advise on study designs, and develop recommendations for aggregating clinical data from registries and other real-world sources. The CORE-MD project (Coordinating Research and Evidence for Medical Devices) will run until March 2024; here we describe how it may contribute to the development of regulatory science in Europe

A comparison of catabolic pathways induced in primary macrophages by pristine single walled carbon nanotubes and pristine graphene

Understanding the correlation between the physico-chemical properties of carbonaceous nanomaterials and how these properties impact on cells and subcellular mechanisms is critical to their risk assessment and safe translation into newly engineered devices. Here the toxicity, uptake and catabolic response of primary human macrophages to pristine graphene (PG) and pristine single walled carbon nanotubes (pSWCNT) are explored, compared and contrasted. The nanomaterial toxicity was assessed using three complementary techniques (live?dead assay, real time impedance technique and confocal microscopic analysis), all of which indicated no signs of acute cytotoxicity in response to PG or pSWCNT. Transmission electron microscopy (TEM) demonstrated that PG was phagocytosed by the cells into single membrane lysosomal vesicles, whereas the primary macrophages exposed to pSWCNT contained many double membrane vesicles indicative of an autophagic response. These distinct catabolic pathways were further verified by biochemical and microscopic techniques. Raman spectroscopic mapping was used to explore the nanomaterial uptake and distribution. Based on the G-band, significant uptake and accumulation of the PG in discrete vesicles was recorded, whereas the pSWCNT were not taken up to the same extent. Thermogravimetric analysis (TGA) of the cells treated with PG revealed that ?20?30% of the remaining dry mass was made up of PG. No detectable amount of pSWCNT was recorded using TGA. TEM analysis confirmed that PG was still graphitic even after 24 hours of accumulation in the lysosomal compartments. In conclusion, these two nanomaterials, with similar surface chemistries but unique geometries, differ significantly in their uptake mechanisms and subsequently induced lysosomal and autophagic catabolic pathways in human primary macrophage

Baseline characteristics of subjects in control and krill oil groups.

<p>Values are mean ± SD.</p

Erythrocyte fatty acid composition in control and krill oil groups at rest pre- and post-supplementation (6 weeks).

<p>Values are mean ± SD. * indicates a significant difference (P<0.05) from baseline values. (c = cis and t = trans)</p

The effect of 6 weeks krill oil/placebo supplementation on heart rate, oxygen consumption and time taken to complete the time trial (pre and post 6 weeks supplementation).

<p>The effect of 6 weeks krill oil/placebo supplementation on heart rate, oxygen consumption and time taken to complete the time trial (pre and post 6 weeks supplementation).</p

The effect of 6 weeks krill oil/placebo supplementation on exercise induced cytokine production by PBMCs stimulated with concanavalin A.

<p>* indicates significant difference (P<0.05) from baseline values. † indicates significant difference (P<0.05) between groups.</p

The effect of 6 weeks krill oil/placebo supplementation on plasma IL-6 and TBARS (expressed as MDA concentration) before and after exercise.

<p>* denotes a significant difference (P<0.05) from baseline in both groups.</p

The effect of 6 weeks krill oil/placebo supplementation on NK cell cytotoxic activity at 50:1 and 25:1 effector:target cell ratio, before and after exercise.

<p>* indicates significant difference (P<0.05) from baseline values. † indicates significant difference between groups.</p